+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-06Number of Pages: 217

Gastrointestinal Drugs Market (Drug Class - Acid Neutralizers (Antacids, H2 Antagonists, and Proton Pump Inhibitors), Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Anti-inflammatory Drugs, Biologics, and Antispasmodic; Route of Administration - Oral, Parenteral and Rectal; Disorder Type - Gastro-esophageal Reflux Disease, Inflammatory Bowel Disease, and Irritable Bowel Syndrome; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Gastrointestinal Drugs Market: Snapshot

The rising prevalence of gastrointestinal diseases across the world is the main factor behind the growth of the global gastrointestinal drugs market. According to the World Gastroenterology Organization, the prevalence of gastroesophageal reflux disease (GERD), worldwide, is approximately 15% to 25%, and the pace of incidence is also quite high. This, as a result, is impacting the demand for gastrointestinal drugs greatly.

Apart from this, the increasing investments in research activities for the development of these drugs and the growing awareness about the availability of the treatments are also adding substantially to the growth of this market. In addition to this, the technological advancements in the treatment therapies are likely to boost this market remarkably in the near future. The overall opportunity in the global gastrointestinal drugs market was worth US$45.5 bn in 2015. Expanding at a CAGR of 4.90% between 2016 and 2024, it is estimated to reach US$61.6 bn by the end of 2024.

gastrointestinal drugs market

 

Rise in Geriatric Population to Ensure Dominance of North America

Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa are the main geographical segments of the worldwide market for gastrointestinal drugs. North America has emerged as the leading regional market for gastrointestinal drugs across the world. Thanks to the presence of consumer-friendly reimbursement policies for the treatment of chronic diseases, it acquired a share of more than 41% in 2016 in the overall market. With the rising number of elderly people, who are prone to gastrointestinal diseases, the North America market for gastrointestinal drugs is likely to maintain its lead over the forthcoming years.

Europe held the second position in the global gastrointestinal drugs market in 2016 and is anticipated to continue being in this position in the near future. The advent of biosimilars for patent-protected brands available for the treatment of inflammatory bowel disease is anticipated to work in the favor of the gastrointestinal drugs market in Europe over the next few years.

Asia Pacific is expected to surface as the most lucrative market for gastrointestinal drugs among others in the years to come. The improvement in the medical and healthcare infrastructure, rise in the private and public investments in life sciences research, and the technological advancements in the treatments of gastrointestinal diseases in emerging economies, such as India and China, are projected to propel the Asia Pacific gastrointestinal drugs market to great extents in the future.

Acid Neutralizers to Witness Continued High Demand

Acid neutralizers, antiemetic and antinauseants, antidiarrheal and laxatives, anti-inflammatory drugs, and biologics are the key drug classes of gastrointestinal drugs. Thanks to the rising prevalence of gastroesophageal reflux disease (GERD), the demand for acid neutralizers has been higher than other gastrointestinal drugs across the world. Owing to its cost efficiency, the segment is likely to maintain the pace of demand over the forthcoming years.

Abbott Laboratories, Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc. are some of the leading players in the global gastrointestinal drugs market.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gastrointestinal Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Gastrointestinal Drugs Market Overview

5. Market Dynamics
     5.1. Drivers
            5.1.1. Restraints
            5.1.2. Opportunity
            5.1.3. Trends 
     5.2. Porter’s Five Force Analysis
     5.3. FDA Approved Biologics Products
     5.4. Overview of Clinical Trials
     5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
     5.6. Global prevalence of Inflammatory Bowel Disease in 2015

6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Size (US$ Mn) Forecast By Drug Class
            6.4.1. Acid Neutralizers
                      6.4.1.1. Antacids
                      6.4.1.2. H2 antagonists
                      6.4.1.3. Proton pump inhibitors
                      6.4.1.4. Helicobacter pylori eradication
            6.4.2. Antidiarrheal and Laxatives
            6.4.3. Antiemetic and Antinauseants
            6.4.4. Anti-inflammatory drugs
            6.4.5. Biologics
            6.4.6. Others (Antispasmodic etc.)
     6.5. Market Attractiveness By Drug Class

7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Size (US$ Mn) Forecast By Route of Administration
            7.4.1. Oral
            7.4.2. Intravenous
            7.4.3. Rectal
     7.5. Market Attractiveness By Route of Administration

8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
     8.1. Introduction & Definition     
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Size (US$ Mn) Forecast By Disorder Type
            8.4.1. Gastroesophageal Reflux Disease
            8.4.2. Inflammatory Bowel Disease
            8.4.3. Irritable Bowel Syndrome
     8.5. Market Attractiveness By Disorder Type

9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Key Trends
     9.4. Market Size (US$ Mn) Forecast By Distribution Channel
            9.4.1. Hospital Pharmacies
            9.4.2. Retail Pharmacies
            9.4.3. Online Pharmacies
     9.5. Market Attractiveness By Distribution Channel

10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
     10.1. Key Findings
     10.2. Policies and Regulations
     10.3. Market Size (US$ Mn) Forecast By Region
            10.3.1. North America
            10.3.2. Latin America
            10.3.3. Europe
            10.3.4. Asia Pacific
            10.3.5. Middle East and Africa
     10.4. Market Attractiveness By Country/Region

11. North America Gastrointestinal Drugs Market Analysis and Forecast     
     11.1. Key Findings
     11.2. Policies and Regulations     
     11.3. Key Trends
     11.4. Market Value Forecast By Country
            11.4.1. US
            11.4.2. Canada
     11.5. Market Size (US$ Mn) Forecast By Drug Class
            11.5.1. Acid Neutralizers
                      11.5.1.1. Antacids
                      11.5.1.2. H2 antagonists
                      11.5.1.3. Proton pump inhibitors
                      11.5.1.4. Helicobacter pylori eradication
            11.5.2. Antidiarrheal and Laxatives
            11.5.3. Antiemetic and Antinauseants
            11.5.4. Anti-inflammatory drugs
            11.5.5. Biologics
            11.5.6. Others (Antispasmodic etc.)
     11.6. Market Size (US$ Mn) Forecast By Route of Administration
            11.6.1. Oral
            11.6.2. Intravenous
            11.6.3. Rectal
     11.7. Market Size (US$ Mn) Forecast By Disorder Type
            11.7.1. Gastroesophageal Reflux Disease
            11.7.2. Inflammatory Bowel Disease
            11.7.3. Irritable Bowel Syndrome
     11.8. Market Size (US$ Mn) Forecast By Distribution Channel
            11.8.1. Hospital Pharmacies
            11.8.2. Retail Pharmacies
            11.8.3. Online Pharmacies
     11.9. Market Attractiveness Analysis 
            11.9.1. By Country
            11.9.2. By Drug Class
            11.9.3. By Route of Administration
            11.9.4. By Disorder Type
            11.9.5. By Distribution Channel

12. Europe Gastrointestinal Drugs Market Analysis and Forecast
     12.1. Key Findings
     12.2. Policies and Regulations
     12.3. Key Trends
     12.4. Market Value Forecast By Country
            12.4.1. Germany
            12.4.2. France
            12.4.3. U.K.
            12.4.4. Italy
            12.4.5. Russia
            12.4.6. Spain
            12.4.7. Rest of Europe
     12.5. Market Size (US$ Mn) Forecast By Drug Class
            12.5.1. Acid Neutralizers
                      12.5.1.1. Antacids
                      12.5.1.2. H2 antagonists
                      12.5.1.3. Proton pump inhibitors
                      12.5.1.4. Helicobacter pylori eradication
            12.5.2. Antidiarrheal and Laxatives
            12.5.3. Antiemetic and Antinauseants
            12.5.4. Anti-inflammatory drugs
            12.5.5. Biologics
            12.5.6. Others (Antispasmodic etc.)
     12.6. Market Size (US$ Mn) Forecast By Route of Administration
            12.6.1. Oral
            12.6.2. Intravenous
            12.6.3. Rectal
     12.7. Market Size (US$ Mn) Forecast By Disorder Type
            12.7.1. Gastroesophageal Reflux Disease
            12.7.2. Inflammatory Bowel Disease
            12.7.3. Irritable Bowel Syndrome
     12.8. Market Size (US$ Mn) Forecast By Distribution Channel
            12.8.1. Hospital Pharmacies
            12.8.2. Retail Pharmacies
            12.8.3. Online Pharmacies
     12.9. Market Attractiveness Analysis 
            12.9.1. By Country
            12.9.2. By Drug Class
            12.9.3. By Route of Administration
            12.9.4. By Disorder Type
            12.9.5. By Distribution Channel

13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
     13.1. Key Findings
     13.2. Policies and Regulations
     13.3. Key Trends
     13.4. Market Value Forecast By Country
            13.4.1. China
            13.4.2. Japan
            13.4.3. India
            13.4.4. Australia & New Zealand
            13.4.5. India
            13.4.6. Rest of Asia Pacific
     13.5. Market Size (US$ Mn) Forecast By Drug Class
            13.5.1. Acid Neutralizers
                      13.5.1.1. Antacids
                      13.5.1.2. H2 antagonists
                      13.5.1.3. Proton pump inhibitors
                      13.5.1.4. Helicobacter pylori eradication
            13.5.2. Antidiarrheal and Laxatives
            13.5.3. Antiemetic and Antinauseants
            13.5.4. Anti-inflammatory drugs
            13.5.5. Biologics
            13.5.6. Others (Antispasmodic etc.)
     13.6. Market Size (US$ Mn) Forecast By Route of Administration
            13.6.1. Oral
            13.6.2. Intravenous
            13.6.3. Rectal
     13.7. Market Size (US$ Mn) Forecast By Disorder Type
            13.7.1. Gastroesophageal Reflux Disease
            13.7.2. Inflammatory Bowel Disease
            13.7.3. Irritable Bowel Syndrome
     13.8. Market Size (US$ Mn) Forecast By Distribution Channel
            13.8.1. Hospital Pharmacies
            13.8.2. Retail Pharmacies
            13.8.3. Online Pharmacies
     13.9. Market Attractiveness Analysis 
            13.9.1. By Country
            13.9.2. By Drug Class
            13.9.3. By Route of Administration
            13.9.4. By Disorder Type
            13.9.5. By Distribution Channel

14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
     14.1. Key Findings
     14.2. Policies and Regulations
     14.3. Key Trends
     14.4. Market Value Forecast By Country
            14.4.1. Brazil
            14.4.2. Mexico
            14.4.3. Rest of Latin America
     14.5. Market Size (US$ Mn) Forecast By Drug Class
            14.5.1. Acid Neutralizers
                      14.5.1.1. Antacids
                      14.5.1.2. H2 antagonists
                      14.5.1.3. Proton pump inhibitors
                      14.5.1.4. Helicobacter pylori eradication
            14.5.2. Antidiarrheal and Laxatives
            14.5.3. Antiemetic and Antinauseants
            14.5.4. Anti-inflammatory drugs
            14.5.5. Biologics
            14.5.6. Others (Antispasmodic etc.)
     14.6. Market Size (US$ Mn) Forecast By Route of Administration
            14.6.1. Oral
            14.6.2. Intravenous
            14.6.3. Rectal
     14.7. Market Size (US$ Mn) Forecast By Disorder Type
            14.7.1. Gastroesophageal Reflux Disease
            14.7.2. Inflammatory Bowel Disease
            14.7.3. Irritable Bowel Syndrome
     14.8. Market Size (US$ Mn) Forecast By Distribution Channel
            14.8.1. Hospital Pharmacies
            14.8.2. Retail Pharmacies
            14.8.3. Online Pharmacies
     14.9. Market Attractiveness Analysis 
            14.9.1. By Country
            14.9.2. By Drug Class
            14.9.3. By Route of Administration
            14.9.4. By Disorder Type
            14.9.5. By Distribution Channel

15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
     15.1. Key Findings
     15.2. Policies and Regulations
     15.3. Key Trends
     15.4. Market Value Forecast By Country
            15.4.1. GCC countries 
            15.4.2. South Africa
            15.4.3. Rest of Middle East & Africa
     15.5. Market Size (US$ Mn) Forecast By Drug Class
            15.5.1. Acid Neutralizers
                      15.5.1.1. Antacids
                      15.5.1.2. H2 antagonists
                      15.5.1.3. Proton pump inhibitors
                      15.5.1.4. Helicobacter pylori eradication
            15.5.2. Antidiarrheal and Laxatives
            15.5.3. Antiemetic and Antinauseants
            15.5.4. Anti-inflammatory drugs
            15.5.5. Biologics
            15.5.6. Others (Antispasmodic etc.)
     15.6. Market Size (US$ Mn) Forecast By Route of Administration
            15.6.1. Oral
            15.6.2. Intravenous
            15.6.3. Rectal
     15.7. Market Size (US$ Mn) Forecast By Disorder Type
            15.7.1. Gastroesophageal Reflux Disease
            15.7.2. Inflammatory Bowel Disease
            15.7.3. Irritable Bowel Syndrome
     15.8. Market Size (US$ Mn) Forecast By Distribution Channel
            15.8.1. Hospital Pharmacies
            15.8.2. Retail Pharmacies
            15.8.3. Online Pharmacies
     15.9. Market Attractiveness Analysis 
            15.9.1. By Country
            15.9.2. By Drug Class
            15.9.3. By Route of Administration
            15.9.4. By Disorder Type
            15.9.5. By Distribution Channel

16. Competition Landscape
     16.1. Market Player 
     16.2. Company Share Analysis (2016)
     16.3. Company Profiles 
            16.3.1. Abbott Laboratories 
                      16.3.1.1. Overview
                      16.3.1.2. Financials
                      16.3.1.3. Recent Developments
                      16.3.1.4. Strategy
            16.3.2. Allergan Plc 
                      16.3.2.1. Overview
                      16.3.2.2. Financials
                      16.3.2.3. Recent Developments
                      16.3.2.4. Strategy
            16.3.3. AstraZeneca 
                      16.3.3.1. Overview
                      16.3.3.2. Financials
                      16.3.3.3. Recent Developments
                      16.3.3.4. Strategy
            16.3.4. Bayer AG 
                      16.3.4.1. Overview
                      16.3.4.2. Financials
                      16.3.4.3. Recent Developments
                      16.3.4.4. Strategy
            16.3.5. Boehringer Ingelheim GmbH 
                      16.3.5.1. Overview
                      16.3.5.2. Financials
                      16.3.5.3. Recent Developments
                      16.3.5.4. Strategy
            16.3.6. GlaxoSmithKline plc 
                      16.3.6.1. Overview
                      16.3.6.2. Financials
                      16.3.6.3. Recent Developments
                      16.3.6.4. Strategy
            16.3.7. Janssen Biotech, Inc. 
                      16.3.7.1. Overview
                      16.3.7.2. Financials
                      16.3.7.3. Recent Developments
                      16.3.7.4. Strategy
            16.3.8. Sanofi
                      16.3.8.1. Overview
                      16.3.8.2. Financials
                      16.3.8.3. Recent Developments
                      16.3.8.4. Strategy
            16.3.9. Takeda Pharmaceutical 
                      16.3.9.1. Overview
                      16.3.9.2. Financials
                      16.3.9.3. Recent Developments
                      16.3.9.4. Strategy
            16.3.10. Valeant Pharmaceuticals, Inc.
                      16.3.10.1. Overview
                      16.3.10.2. Financials
                      16.3.10.3. Recent Developments
                      16.3.10.4. Strategy

List of Figures

Figure 01: Market Value Share, by Drug Class (2015)
Figure 02: Market Value Share, by Route of Administration (2015)
Figure 03: Market Value Share, by Disorder Type (2015)
Figure 04: Market Value Share, by Distribution Channel (2015)
Figure 05: Market Value Share, by Region (2015)
Figure 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 07: Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 08: Global Acid Neutralizers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Antidiarrheal and Laxatives Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Antiemetic and Antinauseants Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Anti-inflammatory drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Biologics Market Revenue (US$ Mn) and
Figure 13: Global Others (Antispasmodic etc.)Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class
Figure 15: Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 16: Global Oral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 17: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 18: Global Rectal Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 20: Global Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 21: Global Gastroesophageal Reflux Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 22: Global Inflammatory Bowel Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 23: Global Irritable Bowel Syndrome Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 24: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 25: Global Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 26: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 27: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 28: Global Online Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 29: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 30: Global Gastrointestinal Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 31: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region
Figure 32: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 33: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 34: North America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 37: North America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 38: North America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 39: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 40: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 41: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 42: North America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 43: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 44: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2015
Figure 45: Europe Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 46: Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 48: Europe Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 49: Europe Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 50: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 51: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 52: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 53: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 54: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 55: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 56: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 57: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 58: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 59: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 60: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 61: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 62: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 63: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 64: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 66: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 67: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 68: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 69: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 70: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 71: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 72: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 73: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 74: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 75: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 76: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 77: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 78: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 79: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 80: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 81: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 82: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 83: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 84: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 85: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 86: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 87: Global Gastrointestinal Drugs Market Share Analysis, by Company, 2016 (Estimated)

List of Tables

Table 01: Biologics Products, Manufacturers & Trade Names 
Table 02: Biologics Products, Manufacturers & Trade Names 
Table 03: Overview of major clinical trials for Inflammatory Bowel Disease
Table 04: Overview of major clinical trials for Inflammatory Bowel Disease
Table 05: Overview of major clinical trials for Inflammatory Bowel Disease
Table 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizer (Drug Class), 2014–2024
Table 08: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 09: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 10: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 11: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 12: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 14: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 15: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 16: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 17: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 18: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 19: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 20: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 21: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 22: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 23: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 24: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 25: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 26: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class),
Table 27: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 28: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 29: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 30: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 31: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 32: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 33: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 34: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 35: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 36: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 37: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 38: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers, 2014–2024
Table 39: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 40: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 41: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

Global Gastrointestinal Drugs Market: Overview 

Gastro esophageal reflux disease (GERD), inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are types of gastrointestinal disease. gastro esophageal reflux disease (GERD) is a chronic gastric illness that arises when acidic juices in the stomach come back up into the esophagus from stomach, this can leads to irritation of esophagus and causes symptoms like heartburn, gas, etc. Inflammatory bowel disease is a group of chronic inflammation of small and large intestine. Ulcerative Colitis and Crohn’s disease are the two major types of inflammatory bowel disease. Irritable bowel syndrome (IBS) is a chronic condition that affects the colon (large intestine). Diarrhea, constipation, abdominal pain, cramping are the common symptoms of irritable bowel disease. 

The market overview section of the report comprises qualitative analysis of the overall gastrointestinal drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the drug class, route of administration, drug class, distribution channel, and key industry developments has also been provided. Key industry developments include the major events occurred in past 4-5 years and are expected to occur during the forecast period which are likely to affect the market dynamics. 

Global Gastrointestinal Drugs Market: Segmentation 

The global gastrointestinal drugs market has been segmented on the basis of drug class, route of administration, drug class, distribution channel. On the basis of drug class the global gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics and others including antispasmodic etc. The acid neutralizer segment is again segmented as antacids, H2 antagonists and Proton pump inhibitors. On the basis of route of administration, the global gastrointestinal drugs market has been segmented into three types such as, oral, parenteral and rectal. Based on disorder type, the global gastrointestinal drugs market is segmented into gastro esophageal reflux disease, inflammatory bowel disease and Irritable bowel syndrome. On the basis of distribution channel, the global gastrointestinal drugs market is segmented as hospital pharmacies, retail pharmacies and online pharmacies. 

The market for these drug class, route of administration, disorder type, and distribution channel has been extensively analyzed on the basis of factors such as usage pattern, sales revenue, and geographic presence and product developments. The market size and forecast in terms of revenue (US$ million), for each of these segments, and the sub-segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024. 

Geographically, the gastrointestinal drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size forecast for each region has been provided for the period 2014 to 2024, in terms of drug class, route of administration, disorder type, and distribution channel, along with the CAGR (%) for the forecast period 2016 to 2024. 

Global Gastrointestinal Drugs Market: Competitive Analysis 

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global gastrointestinal drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. 

The report concludes with the profiles of major players in the global gastrointestinal drugs market such as Takeda pharmaceutical, Valeant Pharmaceuticals International, Inc., Janssen Biotech, Inc., Bayer AG, Sanofi, AstraZeneca, Allergan Plc, GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim GmbH and Allergan Plc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

 The global gastrointestinal drugs market is segmented as follows: 

By Drug Class

  • Acid Neutralizers
    • Antacids
    • H2 antagonists
    • Proton pump inhibitors
  • Antidiarrheal and Laxatives
  • Antiemetic and Antinauseants
  • Anti-inflammatory drugs
  • Biologics
  • Others (Antispasmodic etc.) 

By Route of Administration

  • Oral
  • Parenteral
  • Rectal 

By Disorder Type

  • Gastro Esophageal Reflux Disease
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
    • Southern Global
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top